Novavax (NVAX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Company Performance - Novavax (NVAX) ended the recent trading session at $6.85, showing a -2.28% change from the previous day's closing price, which lagged behind the S&P 500's daily loss of 0.13% [1] - Over the past month, shares of Novavax gained 6.05%, outperforming the Medical sector's loss of 0.96% and the S&P 500's gain of 3.39% [1] Upcoming Earnings - Analysts predict Novavax will report an EPS of -$0.19, indicating a 119.19% decline compared to the same quarter last year [2] - The consensus estimate for quarterly revenue is $118 million, down 71.6% from the year-ago period [2] Annual Forecast - Zacks Consensus Estimates forecast earnings of $2.48 per share and revenue of $1.05 billion for the year, reflecting changes of +301.63% and +53.6%, respectively, compared to the previous year [3] - Recent revisions to analyst forecasts for Novavax are important as they reflect near-term business trends, with positive revisions indicating a favorable business outlook [3] Valuation Metrics - Novavax has a Forward P/E ratio of 2.83, significantly lower than the industry average Forward P/E of 19.79, suggesting that Novavax is trading at a discount [6] - The company currently has a PEG ratio of 0.09, while the Medical - Biomedical and Genetics industry has an average PEG ratio of 1.75 [7] Industry Context - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 91, placing it in the top 37% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]